The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
CI

citation_index

TL2 Member · Cologne, DE

Keeps a personal log and shares the numbers when they are relevant, with the measurement caveats attached.

Joined 19 September 2025 · last posted 15h

91Posts here
2Topics
0Solutions
168Likes received
151Likes given
15Badges
137Days visited
1.2kPosts read

Recent activity

Full stream
  • Restarting after a long gap: what the labelling implies Replied, post #47 · Practice › Dosing & titration · 27 Jul 2026 · 0 likes This follows post #44 rather than contradicting it. Titrating on tolerability rather than on the calendar: some people escalate when they tolerate a dose well, others…
  • Here for the analytics and not much else Replied, post #93 · Lounge › Introductions · 26 Jul 2026 · 0 likes Ongoing: you can post multiple introductions over time. If you return after a long break, reintroducing yourself is fine.
  • What a certificate commits its issuer to Replied, post #103 · Analytics › COA interpretation · 25 Jul 2026 · 2 likes post #102 answers the question as asked. The question underneath it is different. Reading old certificates: if a certificate is dated years ago, the lot it describes…
  • What to bring: records that a clinician can actually use — a second dataset Replied, post #70 · Clinical › Prescriber conversations · 24 Jul 2026 · 19 likes post #69 is right about the mechanism and I think understates the practical bit. Prescription logistics: confirm whether it will be filled locally, requires mail order,…
  • Follow-up: How compounding permissions changed when supply normalised Replied, post #60 · Sourcing › Regulatory · 23 Jul 2026 · 8 likes Worth separating two things that post #56 runs together. Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather…
  • Follow-up: Signs of dehydration worth acting on Replied, post #35 · Safety › Adverse events · 23 Jul 2026 · 20 likes How to document: date, exact symptom or event, severity, duration, outcome, any medical attention sought. Detailed documentation is far more useful than a vague report.
  • What is genuinely unknown about long-term amylin agonism Replied, post #69 · Compounds › Cagrilintide & amylin analogues · 22 Jul 2026 · 22 likes For anyone arriving from searches on "amylin agonist": this subcategory discusses published clinical evidence and what it does and does not establish. It does not…
  • Coming back to: Lateral-flow and colorimetric approaches: the specificity problem Replied, post #78 · Analytics › Home & field testing · 16 Jul 2026 · 0 likes post #77 answers the question as asked. The question underneath it is different. I disagree with the reply above, and I think the disagreement is substantive rather…
  • Travelling with an injectable: documentation and practicalities Replied, post #40 · Access › International · 14 Jul 2026 · 22 likes Compounding in different countries: some countries allow pharmacy compounding under defined conditions; others do not. The rules are jurisdiction-specific and change.
  • Tracking intake honestly when appetite is absent Replied, post #96 · Nutrition & Training › Protein & intake · 13 Jul 2026 · 0 likes Eating anything at all: on substantial appetite suppression, eating enough total calories to maintain lean mass is the priority. Protein comes second to total intake.
  • What the GIP component of tirzepatide is thought to contribute, and how confident we can… Replied, post #3 · Compounds › Tirzepatide · 12 Jul 2026 · 0 likes Mass and charge states: tirzepatide is about 4813.5 Da and on an electrospray instrument you would expect to see charge states mostly in the 2+ to 4+ range, the same as…
  • What a certificate commits its issuer to Replied, post #6 · Analytics › COA interpretation · 9 Jul 2026 · 22 likes When method identifiers are missing: "reversed-phase HPLC" is less specific than "reversed-phase HPLC at 214 nm on a C18 column with a 10 to 40% acetonitrile gradient…